Jim Miller

CDMOs can claim credit for the robust growth of emerging bio/pharma financings.

The industry will see an impact from financing, M&As, advanced therapies, generic drugs, and the retail market in 2018.

Recent acquisitions are creating CDMOs with scale that rivals global bio/pharma.

Mergers and acquisitions are positive for the CDMO industry, but there is a downside.

How has the bio/pharmaceutical contract manufacturing industry evolved and changed over the years and what does the future hold?

CMOs may be gaining as strategic partners to large bio/pharma companies, but they have a much harder path to navigate.

Moving global manufacturing operations may be more complicated than it appears.

Robust venture capital investment gives CDMOs and CROs a positive outlook for 2017.

CMO executives are focusing on M&A activity, new business models, and fundraising limits.

The strategies of a innovation-driven CMO may be different than a capacity-driven CMO.